Compare Amgen, Inc. (AMGN) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Wynn Resorts, Limited — how do they compare? Amgen, Inc. trades at $362.11 (market cap $196.12B), while Wynn Resorts, Limited trades at $99.4 (market cap $10.35B). The key difference: Amgen, Inc. is far larger — about 18.9× Wynn Resorts, Limited's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WYNN | |
|---|---|---|
Market Cap | $196.12B | $10.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $133.34 |
52-Week Low | $271.18 | $94.78 |
Enterprise Value | $241.41B | $20.72B |
Dividend Yield | 2.77% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Wynn Resorts (WYNN) trades at $99.77, up 0.95% on the day, but remains 13.4% down year-to-date amid bearish technical signals. The company reported Q1 2026 EPS of $1.25, meeting expectations, but has missed estimates in three of the last four quarters. Revenue growth continues with $7.14B in 2025, though net margins have compressed from 11.17% in 2023 to 4.58% in 2025. High debt levels persist with $10.50B long-term debt, while analyst consensus remains strongly bullish with a $134.60 price target.
The outlook is mixed: strong analyst support and luxury market positioning offer upside potential, but margin pressure, high leverage, and recent earnings misses present significant risks. The stock's current valuation at 28.59 P/E appears stretched given declining profitability, making execution on future growth critical for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
